Business
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investment bank conferences ...
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in two investment bank conferences taking place in June 2026.","length":300,"tagName":"p"},{"type":"text","content":"2026 Jefferies Global Healthcare Conference; New York, NY - June 2-4, 2026","length":74,"tagName":"p"},{"type":"text","content":"Format: Fireside Chat","length":21,"tagName":"p"},{"type":"text","content":"Day/Time: Wednesday, June 3 at 9:55 A.M. ET","length":43,"tagName":"p"},{"type":"text","content":"Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/STGS2oumT8ZPxxrEhwVAR5","length":88,"tagName":"p"},{"type":"text","content":"Goldman Sachs 47th Annual Global Healthcare Conference 2026; Miami, FL - June 8-10, 2026","length":88,"tagName":"p"},{"type":"text","content":"Format: Fireside Chat","length":21,"tagName":"p"},{"type":"text","content":"Day/Time: Wednesday, June 10 at 9:20 A.M. ET","length":44,"tagName":"p"},{"type":"text","content":"Webcast: https://event.webcasts.com/starthere.jsp?ei=1764366&tp_key=bf1c052870&tp_special=8","length":99,"tagName":"p"},{"type":"text","content":"If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.","length":145,"tagName":"p"},{"type":"text","content":"A replay of the presentations will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.","length":154,"tagName":"p"},{"type":"text","content":"About Protagonist","length":17,"tagName":"p"},{"type":"text","content":"Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in ad...